Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Massachusetts General Hospital, Harvard Medical School, Boston.
JAMA Netw Open. 2024 Aug 1;7(8):e2427248. doi: 10.1001/jamanetworkopen.2024.27248.
Depressive symptoms in older adults may be a harbinger of Alzheimer disease (AD), even in preclinical stages. It is unclear whether worsening depressive symptoms are manifestations of regional distributions of core AD pathology (amyloid) and whether cognitive changes affect this relationship.
To evaluate whether increasing depressive symptoms are associated with amyloid accumulation in brain regions important for emotional regulation and whether those associations vary by cognitive performance.
DESIGN, SETTING, AND PARTICIPANTS: Participants from the Harvard Aging Brain Study, a longitudinal cohort study, underwent annual assessments of depressive symptoms and cognition alongside cortical amyloid positron emission tomography (PET) imaging at baseline and every 2 to 3 years thereafter (mean [SD] follow-up, 8.6 [2.2] years). Data collection was conducted from September 2010 to October 2022 in a convenience sample of community-dwelling older adults who were cognitively unimpaired with, at most, mild baseline depression. Data were analyzed from October 2022 to December 2023.
Depression (Geriatric Depression Scale [GDS]-30-item), cognition (Preclinical Alzheimer Cognitive Composite-5 [PACC]), and a continuous measure of cerebral amyloid (Pittsburgh compound B [PiB] PET) examined in a priori-defined regions (medial orbitofrontal cortex [mOFC], lateral orbitofrontal cortex, middle frontal cortex [MFC], superior frontal cortex, anterior cingulate cortex, isthmus cingulate cortex [IC], posterior cingulate cortex, and amygdala). Associations between longitudinal GDS scores, regional amyloid slopes, and PACC slopes were assessed using linear mixed-effects models.
In this sample of 154 individuals (94 [61%] female; mean [SD] age, 72.6 [6.4] years; mean (SD) education, 15.9 [3.1] years), increasing PiB slopes in the bilateral mOFC, IC, and MFC were associated with increasing GDS scores (mOFC: β = 11.07 [95% CI, 5.26-16.87]; t = 3.74 [SE, 2.96]; P = .004; IC: β = 12.83 [95% CI, 5.68-19.98]; t = 3.51 [SE, 3.65]; P = .004; MFC: β = 9.22 [95% CI, 2.25-16.20]; t = 2.59 [SE, 3.56]; P = .03). Even with PACC slope as an additional covariate, associations remained significant in these regions.
In this cohort study of cognitively unimpaired older adults with, at most, mild baseline depressive symptoms, greater depressive symptoms over time were associated with amyloid accumulation in regions associated with emotional control. Furthermore, these associations persisted in most regions independent of cognitive changes. These results shed light on the neurobiology of depressive symptoms in older individuals and underscore the importance of monitoring for elevated mood symptoms early in AD.
老年人的抑郁症状可能是阿尔茨海默病(AD)的预兆,即使在临床前阶段也是如此。目前尚不清楚抑郁症状的恶化是否是 AD 核心病理(淀粉样蛋白)的区域分布的表现,以及认知变化是否会影响这种关系。
评估抑郁症状的加重是否与大脑中与情绪调节相关的区域的淀粉样蛋白积累有关,以及这些关联是否因认知表现而异。
设计、地点和参与者:本研究参与者来自哈佛老化大脑研究(Harvard Aging Brain Study),这是一项纵向队列研究,在基线时以及此后每 2 至 3 年(平均[SD]随访时间为 8.6[2.2]年)进行年度抑郁症状和认知评估,以及皮质淀粉样蛋白正电子发射断层扫描(PET)成像。数据采集在认知无障碍的社区居住的老年人便利样本中进行,这些老年人在基线时有,最多有轻度抑郁。数据分析于 2022 年 10 月至 2023 年 12 月进行。
使用老年抑郁量表(GDS-30 项)、认知(Preclinical Alzheimer Cognitive Composite-5 [PACC])和预先定义区域(内侧眶额皮层[mOFC]、外侧眶额皮层、中额皮质[MFC]、额上回、前扣带皮层、峡部扣带皮层[IC]、后扣带皮层和杏仁核)的放射性示踪剂[Pittsburgh 复合 B(PiB)PET]测量大脑中的淀粉样蛋白。使用线性混合效应模型评估纵向 GDS 评分、区域淀粉样蛋白斜率和 PACC 斜率之间的关联。
在这项研究中,共有 154 名参与者(94[61%]名女性;平均[SD]年龄 72.6[6.4]岁;平均[SD]教育程度 15.9[3.1]年),双侧 mOFC、IC 和 MFC 中 PiB 斜率的增加与 GDS 评分的增加有关(mOFC:β=11.07[95%CI,5.26-16.87];t=3.74[SE,2.96];P=0.004;IC:β=12.83[95%CI,5.68-19.98];t=3.51[SE,3.65];P=0.004;MFC:β=9.22[95%CI,2.25-16.20];t=2.59[SE,3.56];P=0.03)。即使将 PACC 斜率作为额外的协变量,这些区域的关联仍然显著。
在这项对认知无障碍的老年人进行的队列研究中,他们的抑郁症状最多只有轻度基线抑郁,随着时间的推移,抑郁症状的加重与与情绪控制相关的区域的淀粉样蛋白积累有关。此外,在大多数区域,这些关联在独立于认知变化的情况下仍然存在。这些结果揭示了老年个体抑郁症状的神经生物学,并强调了早期监测 AD 中情绪症状升高的重要性。